Skip to main content
Premium Trial:

Request an Annual Quote

Siegel Leaves Affy for VC Shop; Fraser-Liggett Says Goodbye to TIGR; Tripos Rearranges Brass; and Others

NEW YORK (GenomeWeb News) — Sue Siegel has resigned fromas president emeritus of Affymetrix, and was named a partner at the Silicon Valley venture-capital firm Mohr Davidow Ventures.
Siegel became president of the company in 1999 and a director in 2001. She became president emeritus in 2006 after resigning as president and director in 2006.
Under her 2006 contract agreement, Siegel will receive a payment of $675,000, minus what she has received of her salary of $426,000 since April 19, 2006, and stock options vested through Oct. 19, 2007.
At MDV, Siegel will help the company “invest in cross-discipline companies” involved in clinical and medical technological development.
Siegel said MDV has a demonstrated commitment to “making personalized medicine more than a catch phrase” by investing in life sciences start-up companies, and drug and diagnostic discovery.

Claire Fraser-Liggett has resigned as president of the Institute for Genomic Research, GenomeWeb Daily News learned this week.
Fraser-Liggett will leave TIGR on April 20. It was not immediately clear who will take her place at TIGR, which is a division of the J. Craig Venter Institute.
News of Fraser-Liggett’s departure was disclosed in an e-mail sent to JCVI colleagues by Craig Venter, JCVI president and CEO, which said she will leave “to pursue a new position.”
Fraser-Liggett, who is Venter’s former wife, has been TIGR president and director since September 1998. Her decision to resign comes five months after TIGR and the J. Craig Venter Science Foundation consolidated under the JCVI in early October.
Following the consolidation, Venter became president and chief executive officer of JCVI. Fraser-Liggett remained as president of TIGR, which became a division of the JCVI.

Genstruct has appointed Christian Reich vice president of scientific research, the company said this week. Reich will run the company’s internal research teams and translational medicine and clinical research programs with teaming partners.
Reich is a physician and formerly worked at the Human Genome Project, the European Bioinformatics Institute, and Millennium Pharmaceuticals.

DeltaDot this week said it has named Richard Lingard vice president of sales. Lingard previously was a director of strategic alliances at Invitrogen, vice president of business development at Argenta Discovery, director of business development at Inpharmatics, and was a sales director at Genomica. Lingard also served in business positions at Accelyrs and at Merck.

Jim Hopkins has been named CEO of Tripos Discovery Informatics, now a private company after it was sold recently to Vector Capital. The company also named Richard Cramer as CSO and Robert Clark as vice president of research.
Hopkins formerly was chairman and CEO of Micrografx, and has experience moving companies toward initial public offerings and buying and selling private and public companies.
Cramer has been vice president of science at Tripos for 24 years. He is an inventor and was chief technical officer at STATS, a sports statistical information company.
Clark was vice president of scientific research and director of the informatics research center at Tripos, and worked at Monsanto on bio-molecule discovery and development.
Tripos also said that John Yingling, CFO; Richard Cramer, CSO; and Dieter Schmidt-Base, senior vice president of worldwide sales; resigned from their positions with Tripos to accept positions with Vector Capital, which completed its acquisition of the Tripos Discovery Informatics business this week. 
In addition, Tripos said that it has terminated the employment of James Rubin, senior vice president; Bryan Koontz, senior vice president of discovery informatics; and Mary Woodward, senior vice president of strategic development. 

Susie Stephens, formerly senior product manager for Oracle's life sciences group, has left Oracle to join Eli Lilly as a principal research scientist.

Cellexus Biosystems has named Julie Bick its new CSO, the company said this week. Bick will lead the company’s research and customer-support programs for its US subsidiary Cellexus Biosystems, Inc.
She previously worked on protein-expression systems at Sanofi-Aventis.
Bick is experienced in cell culture, protein engineering, assay development, gene cloning, kinase studies, and other disciplines, Cellexus said.

Upstream Biosciences has appointed Phil Rice to its board of directors, the company said this week. Rice previously worked as treasurer for Transamerica was a director of Dresdner Kleinworth Wasserstein, and has investment banking experience with Oracle, Morgan Stanley Capital Group, and Goldman Sachs.

MorphoSys this week said that Andreas Plückthun will resign from the company’s supervisory board on May 16. The board has proposed that he be replaced by Walter Blättler, who formerly was executive vice president of science and technology at ImmonoGen.
Plückthun, who founded MorphoSys in 1992, will remain with the company in an advisory capacity, MorphoSys said.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.